Korro Bio is trading at $10.28, up 10.66%, after announcing positive KRRO-111 preclinical results. - On October 22, the company reported up to 95% lower pathogenic liver Z-AAT in mice. - Results included more than 95% SERPINA1 mRNA editing; Korro Bio says KRRO-111 could address both lung and liver manifestations of alpha-1 antitrypsin deficiency. - The announcement is the clearest company-specific catalyst for the gain, but the release did not discuss the trading reaction.